FDA: Test before giving GSK med

Personalized medicine, here we come--at least that's the message in two genetic-testing developments today. First, the FDA is advising docs to screen HIV patients for a particular genetic variant before prescribing abacavir, a GlaxoSmithKline anti-AIDS med sold under the brand name Ziagen and as part of the combo treatments Trizivir and Epzicom. That's because people with that genetic variation are at a far higher risk of a severe allergic reaction.

Though that risk was first reported several years ago, it was only recently quantified in a clinical trial. The genetic test will be recommended in a "black box" warning on abacavir labeling. With this move, abacavir becomes one of only a handful of meds for which the FDA has recommended genetic screening--but we can expect more to come.

Second, a new study tagged a particular variant with statins' most serious side effect. People who have that genetic variation were five to 17 times more likely to develop muscle pain and weakness--which can lead to muscle breakdown, kidney failure and death--when taking the cholesterol-lowering meds. The finding could lead to a predictive genetic test, which could help doctors know which patients can tolerate the higher doses that are increasingly common amongst statin-users.

- read the abacavir news from the New York Times
- check out the Washington Post statin story

Suggested Articles

Post-Tesaro buyout, don’t expect GlaxoSmithKline to spring for more commercial-stage oncology products anytime soon.

Already a fast-growing blockbuster, Novo Nordisk's injectable Ozempic won a major heart-helping FDA nod that could bode well for its oral sibling.

Bayer's new Vitrakvi for tumors with NTRK gene fusions is meeting skepticism in England and Germany, where cost watchdogs on Friday rejected it.